

**HER2-POSITIVE TARGETED THERAPY  
TOTAL PRESCRIPTIONS  
U.S. UNITS BY PRODUCT  
Q4 2012 – Q3 2014**

	2012	2013			
	Q4	Q1	Q2	Q3	Q4
<b>IV</b>					
Herceptin®	1,024	1,051	992	1,057	1,034
Kadcyla® <sup>1</sup>		14	145	257	314
Perjeta®	140	180	214	187	217
Total	1,164	1,245	1,351	1,501	1,565
<b>IV</b>					
Herceptin®	88.0%	84.4%	73.4%	70.4%	66.1%
Kadcyla®		1.1%	10.7%	17.1%	20.1%
Perjeta®	12.0%	14.5%	15.8%	12.5%	13.9%
Total	100.0%	100.0%	100.0%	100.0%	100.0%

Notes & Sources:

<sup>1</sup> Annual Kadcyla® prescriptions totaled 730 in 2013.

Kadcyla® is indicated as a single agent for the treatment of people with HER2-positive metastatic breast cancer with chemotherapy. See, e.g., Exhibit 2317. In contrast:

Xeloda® can be used to treat colon, rectal, and other cancers. See, e.g., Exhibit 2246.

Perjeta® received FDA approval for neoadjuvant breast cancer therapy. See, e.g., Exhibit 2211.

Tykerb® is used to treat breast cancer, but is prescribed with a second medicine (Xeloda® or Femara®). See, e.g., Exhibit 2211. (These assertions and sources can be found in the report.)

Includes brand values.

Herceptin® includes brand HERCEPTIN 10/1998 GTC, identified in field 'Product.'

Kadcyla® includes brand KADCYLA 02/2013 GTC, identified in field 'Product.'

Perjeta® includes brand PERJETA 06/2012 GTC, identified in field 'Product.'

Values reflect field 'TRx'.

Percentage calculated as percent of quarterly total.

Products identified from Exhibit 2103 and Exhibit 2224.

Data from IMS Health.